Papers
8
Total Citations
409
H-Index
7
About
Ravi Marudanayagam is a leading hepatopancreaticobiliary surgeon whose research has fundamentally reshaped the surgical management of pancreatic cancer, particularly through the rigorous evaluation of minimally invasive techniques. His work centers on comparing robotic, laparoscopic, and open distal pancreatectomy, with a focus on oncological safety and perioperative outcomes. Marudanayagam was instrumental in the landmark DIPLOMA trial—the first international randomised non-inferiority study to confirm that minimally invasive distal pancreatectomy is a safe alternative to open surgery for resectable pancreatic cancer, a finding that has influenced global practice. His multicentre analyses, including a 2021 study comparing robotic versus laparoscopic distal pancreatectomy (121 citations), have provided critical evidence on the benefits and learning curves of these advanced approaches. With multiple highly cited papers, including the DIPLOMA protocol and a 2023 robotic cohort study, his cumulative impact exceeds 400 citations. Marudanayagam’s work has established benchmarks for minimally invasive pancreatic surgery, offering surgeons and patients clearer guidance on optimal treatment pathways for this challenging disease.
Research Focus
Key Achievements
Top Papers
- 1Robotic <i>versus</i> laparoscopic distal pancreatectomy: multicentre analysis121 citations · 2021
- 2
- 3
- 4
- 5
- 6
- 7
- 8